ArticleThe oncologist2021

Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.

Kartik Sehgal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.